Moors & Cabot’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.6M | Sell |
96,078
-1,894
| -2% | -$219K | 0.49% | 43 |
|
|
2025
Q4 | $10.3M | Buy |
97,972
+5,726
| +6% | +$538K | 0.44% | 42 |
|
|
2025
Q3 | $7.74M | Sell |
92,246
-19,907
| -18% | -$1.64M | 0.34% | 55 |
|
|
2025
Q2 | $8.88M | Sell |
112,153
-19,314
| -15% | -$1.54M | 0.41% | 48 |
|
|
2025
Q1 | $11.8M | Sell |
131,467
-12,450
| -9% | -$1.16M | 0.6% | 33 |
|
|
2024
Q4 | $14.3M | Sell |
143,917
-477
| -0.3% | -$49.2K | 0.68% | 28 |
|
|
2024
Q3 | $16.4M | Sell |
144,394
-867
| -0.6% | -$103K | 0.81% | 21 |
|
|
2024
Q2 | $18M | Buy |
145,261
+1,083
| +0.8% | +$140K | 0.96% | 16 |
|
|
2024
Q1 | $19M | Buy |
144,178
+2,131
| +2% | +$263K | 1.03% | 14 |
|
|
2023
Q4 | $15.5M | Sell |
142,047
-1,221
| -0.9% | -$127K | 0.96% | 15 |
|
|
2023
Q3 | $14.7M | Sell |
143,268
-2,871
| -2% | -$309K | 1% | 15 |
|
|
2023
Q2 | $16.9M | Sell |
146,139
-1,049
| -0.7% | -$119K | 1.12% | 12 |
|
|
2023
Q1 | $15.7M | Sell |
147,188
-3,699
| -2% | -$399K | 1.08% | 13 |
|
|
2022
Q4 | $16.7M | Buy |
150,887
+3,390
| +2% | +$347K | 1.17% | 12 |
|
|
2022
Q3 | $12.7M | Sell |
147,497
-2,970
| -2% | -$265K | 0.97% | 15 |
|
|
2022
Q2 | $13.7M | Buy |
150,467
+5,040
| +3% | +$447K | 0.99% | 17 |
|
|
2022
Q1 | $11.9M | Buy |
145,427
+13,544
| +10% | +$1.07M | 0.73% | 22 |
|
|
2021
Q4 | $10.1M | Buy |
131,883
+2,307
| +2% | +$184K | 0.62% | 29 |
|
|
2021
Q3 | $9.77M | Buy |
129,576
+12,287
| +10% | +$934K | 0.61% | 26 |
|
|
2021
Q2 | $9.12M | Sell |
117,289
-5,705
| -5% | -$424K | 0.64% | 29 |
|
|
2021
Q1 | $9.05M | Sell |
122,994
-2,510
| -2% | -$185K | 0.69% | 25 |
|
|
2020
Q4 | $9.78M | Sell |
125,504
-126
| -0.1% | -$9.64K | 0.82% | 22 |
|
|
2020
Q3 | $9.94M | Sell |
125,630
-1,107
| -0.9% | -$86.7K | 0.94% | 18 |
|
|
2020
Q2 | $9.35M | Buy |
126,737
+6,569
| +5% | +$495K | 1% | 14 |
|
|
2020
Q1 | $8.81M | Sell |
120,168
-7,660
| -6% | -$602K | 1.28% | 11 |
|
|
2019
Q4 | $11.1M | Buy |
127,828
+764
| +0.6% | +$62.8K | 1.11% | 15 |
|
|
2019
Q3 | $10.2M | Buy |
127,064
+7,387
| +6% | +$592K | 1.12% | 16 |
|
|
2019
Q2 | $9.58M | Buy |
119,677
+2,844
| +2% | +$218K | 1.21% | 13 |
|
|
2019
Q1 | $9.27M | Buy |
116,833
+3,391
| +3% | +$254K | 1.26% | 11 |
|
|
2018
Q4 | $8.26M | Sell |
113,442
-9,916
| -8% | -$700K | 1.3% | 12 |
|
|
2018
Q3 | $8.34M | Buy |
123,358
+91
| +0.1% | +$5.8K | 1.02% | 16 |
|
|
2018
Q2 | $7.12M | Buy |
123,267
+1,498
| +1% | +$84.5K | 0.96% | 19 |
|
|
2018
Q1 | $6.33M | Buy |
121,769
+7,736
| +7% | +$418K | 0.84% | 19 |
|
|
2017
Q4 | $6.12M | Buy |
114,033
+13,104
| +13% | +$726K | 0.81% | 18 |
|
|
2017
Q3 | $6.16M | Buy |
100,929
+22,740
| +29% | +$1.38M | 0.89% | 19 |
|
|
2017
Q2 | $4.78M | Buy |
78,189
+1,551
| +2% | +$94.4K | 0.79% | 19 |
|
|
2017
Q1 | $4.65M | Sell |
76,638
-600
| -0.8% | -$36.4K | 0.78% | 22 |
|
|
2016
Q4 | $4.35M | Buy |
77,238
+164
| +0.2% | +$9.6K | 0.72% | 22 |
|
|
2016
Q3 | $4.57M | Sell |
77,074
-4,270
| -5% | -$250K | 0.76% | 20 |
|
|
2016
Q2 | $4.49M | Buy |
81,344
+359
| +0.4% | +$19.1K | 0.79% | 19 |
|
|
2016
Q1 | $4.09M | Buy |
80,985
+959
| +1% | +$47K | 0.74% | 24 |
|
|
2015
Q4 | $4.04M | Buy |
80,026
+1,292
| +2% | +$65.1K | 0.74% | 22 |
|
|
2015
Q3 | $3.72M | Sell |
78,734
-1,066
| -1% | -$56.6K | 0.69% | 24 |
|
|
2015
Q2 | $4.32M | Sell |
79,800
-1,340
| -2% | -$75.2K | 0.7% | 28 |
|
|
2015
Q1 | $4.43M | Sell |
81,140
-1,607
| -2% | -$91K | 0.74% | 25 |
|
|
2014
Q4 | $4.48M | Sell |
82,747
-1,320
| -2% | -$73.5K | 0.76% | 24 |
|
|
2014
Q3 | $4.77M | Buy |
84,067
+1,266
| +2% | +$71.1K | 0.81% | 23 |
|
|
2014
Q2 | $4.58M | Buy |
82,801
+6,020
| +8% | +$328K | 0.77% | 25 |
|
|
2014
Q1 | $4.16M | Buy |
+76,781
| New | +$3.98M | 1.05% | 16 |
|
Other funds holding MRK
VCM
VPM
Moors & Cabot's MRK Position: Q1 2026 in Review
Moors & Cabot reduced its Merck (MRK) stake by 1.9% in Q1 2026, selling an estimated $219K and leaving 96,078 shares worth $11.6M. The position accounts for 0.49% of the portfolio, ranked #43.
Moors & Cabot first reported a position in MRK in Q1 2014 and has held it in 49 quarters since. The position peaked at $19M in Q1 2024. 3,779 funds tracked by Wall St. Rank hold MRK as of Q1 2026.
- Moors & Cabot held 96,078 shares of Merck worth $11.6M as of Q1 2026.
- Moors & Cabot sold 1,894 Merck shares in Q1 2026, an estimated $219K.
- Merck made up 0.49% of Moors & Cabot's portfolio in Q1 2026, its #43 holding.
- Moors & Cabot first reported a position in Merck in Q1 2014 and has held it in 49 quarters since.
- Moors & Cabot's Merck position peaked at $19M in Q1 2024.
- 3,779 funds tracked by Wall St. Rank held Merck as of Q1 2026.
Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.